
Claims

1. Use of obicetrapib, the compound having the structural formula:



(I)

or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of a subject suffering from or at risk of suffering from cardiovascular disease (CVD), in particular Atherosclerotic cardiovascular disease (ASCVD), wherein the subject is a hypo-responder to high-intensity statin (HIS) therapy, wherein hypo-responsiveness to HIS therapy means that a subject receiving HIS therapy fails to reach a 35 % LDL-C reduction, as established after at least 1 month of (continuous) HIS therapy, and wherein high-intensity statin therapy denotes a statin regimen selected from the group consisting of 20 mg rosuvastatin daily; 40 mg rosuvastatin daily; 40 mg atorvastatin daily; and 80 mg atorvastatin daily, and wherein the prophylactic and/or therapeutic treatment further comprises concomitant statin therapy.

2. The use according to claim 1, wherein the subject is a subject that is receiving HIS therapy and fails to reach a 35 % LDL-C reduction.

3. The use according to claim 1, wherein the prophylactic and/or therapeutic treatment comprises oral administration of obicetrapib or a pharmaceutically acceptable salt, hydrate or solvate thereof.

4. The use according to any one of the preceding claims, wherein the prophylactic and/or therapeutic treatment comprises oral administration of obicetrapib or a

pharmaceutically acceptable salt, hydrate or solvate thereof at a dose of 4-25 mg or of a salt, solvate or hydrate of obicetrapib in the equipotent dose.

5. The use according to any one of the preceding claims, wherein the prophylactic and/or therapeutic treatment comprises oral administration of obicetrapib or a pharmaceutically acceptable salt, hydrate or solvate thereof at a dose of 5 mg, or of a salt, solvate or hydrate of obicetrapib in the equipotent dose.

6. The use according to any one of the preceding claims, wherein the prophylactic and/or therapeutic treatment comprises oral administration of obicetrapib or a pharmaceutically acceptable salt, hydrate or solvate thereof at a dose of 10 mg, or of a salt, solvate or hydrate of obicetrapib in the equipotent dose.

7. The use according to any one of the preceding claims, wherein the prophylactic and/or therapeutic treatment comprises the once daily administration of obicetrapib or a salt, solvate or hydrate thereof.

8. The use according to any one of the preceding claims, wherein the prophylactic and/or therapeutic treatment comprises the administration of atorvastatin in a daily dosage within the range of 70-90 mg.

9. The use according to any one of the preceding claims, wherein the prophylactic and/or therapeutic treatment comprises the administration of rosuvastatin in a daily dosage within the range of 30-50 mg.

10. The use according to any one of the preceding claims, wherein the subject has elevated plasma levels of LDL-C of at least 70 mg/dL after at least 3 months of continuous HIS therapy.

11. The use according to any one of the preceding claims, wherein the prophylactic and/or therapeutic treatment is effective in and/or intended for reducing LDL-C plasma levels with at least 25 mg/dL, from baseline, wherein baseline is defined as start of the treatment with obicetrapib as an add-on to HIS therapy.

12. The use according to any one of the preceding claims, wherein the subject to be treated has elevated plasma levels of ApoB of at least 70 mg/dL after at least 3 months of continuous HIS therapy.

13. The use according to any one of the preceding claims, wherein the prophylactic and/or therapeutic treatment is effective in and/or intended for reducing ApoB plasma levels, with at least 25 mg/dL, from baseline, wherein baseline is defined as start of the treatment with obicetrapib as an add-on to HIS therapy.

14. The use according to any one of the preceding claims, wherein the prophylactic and/or therapeutic treatment comprises repeated administration of the composition containing obicetrapib or a salt, hydrate or solvate thereof, during a period of at least six months.

15. The use according to any one of the preceding claims, wherein the subject is a subject suffering diabetes, hypertension, hypercholesterolemia, overweight/obesity and/or metabolic syndrome.